

The Association of Pulmonary Functions with Glycemic Control and Microvascular Complications in Patients with Type II Diabetes Mellitus

Tip II Diabetes Mellitus'lu Hastalarda Solunum Fonksiyonlarının Glisemik Kontrol ve Mikrovasküler Komplikasyonlar İle İlişkisi

Gülşay Ulusal Okyay¹, Ezgi Coşkun Yenigün¹, Ahmet Hondur², Yıldız Çoruh³,
Çağla Pınar Taştan Uzunmehmetoğlu⁴, İsmail Safa Yıldırım¹

Abstract / Özet

Objective: Pulmonary system is a target organ for microangiopathic damage in patients with diabetes mellitus (DM). In the present study, the relationships of pulmonary functions with glycemic control, duration of diabetes, and microangiopathic complications have been assessed in type II diabetic patients.

Methods: Thirty-one type II diabetic patients with no history of either smoking or cardiopulmonary diseases were enrolled into the study. Blood tests including glycosylated hemoglobin (HbA1c) were performed. Pulmonary functions were assessed with spirometry and carbon monoxide (CO) diffusion capacity.

Results: Pulmonary functions were as follows: FEV₁ (%): 93.88±16.12; FVC (%): 86.48±15.76; FEV₁/FVC: 94.79±12.34; DL_{CO} (mL/min/mm Hg): 104.13±15.00; and DL_{VA} (mL/min/mmHg/l): 103.26±13.00. Eleven patients (35.4%) had diabetic nephropathy, 11 patients (35.4%) had retinopathy, 10 patients (32.3%) had sensorimotor neuropathy, and 10 patients (32.3%) did not have any microangiopathic complications. After adjustment for age, gender, and body mass index, there were significant associations between HbA1c and FEV₁ (p=0.024; r=-0.426), FVC (p=0.009, r=-0.482), and FEV₁/FVC ratio (p=0.028, r=0.415). No association was observed between HbA1c and CO diffusion capacity measurements (for all p>0.05). There was no significant relationship between the duration of diabetes and pulmonary functions (for all p>0.05). Pulmonary function tests were found similar between patients having microangiopathic complications and those without them.

Conclusion: Poor glycemic control may cause functional alterations of restrictive type in patients with type II DM.

Keywords: Diabetes mellitus, glycemic control, microangiopathic complications, pulmonary functions

Amaç: Solunum sistemi, diyabetik hastalarda mikroanjyopatik hasar için bir hedef organdır. Bu çalışmada, tip II diyabetli hastalarda pulmoner fonksiyonların glisemik kontrol, diyabet süresi ve mikroanjyopatik komplikasyonlar ile ilişkileri incelenmiştir.

Yöntemler: Sigara içme öyküleri ve tanımlanmış kardiyopulmoner hastalığı bulunmayan 31 tip II diyabetik hasta çalışmaya dahil edildi. Hastaların rutin kan tetkikleri yanında glisolize hemoglobin (HbA1c) düzeyleri ölçüldü. Solunum fonksiyonları spirometri ve karbonmonoksit difüzyon kapasitesi ölçümleri ile değerlendirildi.

Bulgular: Solunum fonksiyon testlerinin sonuçları; FEV₁ (%): 93,88±16,12, FVC (%): 86,48±15,76, FEV₁/FVC: 94,79±12,34, DLCO (mL/min/mmHg): 104,13±15,00 ve DLVA (mL/min/mmHg/l): 103,26±13,00 şeklinde idi. Hastalarımızın 11'inde (35,4%) diyabetik nefropati, 11'inde diyabetik retinopati (35,4%) ve 10'unda (32,3%) sensorimotor nöropati saptandı. 10 hastada (32,3%) tanımlanan mikroanjyopatik komplikasyonların hiçbirisi yoktu. Yaş, cinsiyet ve vücut kitle indeksine göre düzenlenmiş analizde, HbA1c ile FEV₁ (p=0,024, r=-0,426), FVC (p=0,009, r=-0,482) ve FEV₁/FVC oranı (p=0,028, r=0,415) arasında anlamlı ilişkiler saptandı. HbA1c'nin, difüzyon kapasitesi ölçümleri ile ilişkisi gözlenmedi (hepsi için, p>0,05). Diyabetes mellitus süresi ile solunum fonksiyonları arasında anlamlı bir ilişki saptanmadı (hepsi için, p>0,05). Mikroanjyopatik komplikasyonları olan ve olmayan hastalarda solunum fonksiyonları benzerdi.

Sonuç: Kötü glisemik kontrol, tip II diyabetik hastalarda restriktif tipte fonksiyonel değişikliklere yol açabilir.

Anahtar Kelimeler: Diyabetes mellitus, glisemik kontrol, mikroanjyopatik komplikasyonlar, solunum fonksiyonları

¹Clinic of Internal Medicine, Diskapi Yıldırım Beyazıt Training and Research Hospital, Ankara, Türkiye

²Department of Ophthalmology, Gazi University Faculty of Medicine, Ankara, Türkiye

³Clinic of Neurology, Diskapi Yıldırım Beyazıt Education and Research Hospital, Ankara, Türkiye

⁴Clinic of Chest Disease and Tuberculosis, Diskapi Yıldırım Beyazıt Education and Research Hospital, Ankara, Türkiye

Address for Correspondence

Yazışma Adresi:

Gülşay Ulusal Okyay, Clinic of Internal Medicine, Diskapi Yıldırım Beyazıt Training and Research Hospital, Ankara, Türkiye
Phone: +90 312 341 03 15
E-mail: mdgulayulusal@hotmail.com

Received/Geliş Tarihi:
09.09.2014

Accepted/Kabul Tarihi:
13.03.2015

© Copyright 2015 by Available online at
www.istanbulmedicaljournal.org

© Telif Hakkı 2015 Makale metnine
www.istanbultipdergisi.org web sayfasından
ulaşılabilir.

Introduction

Diabetes mellitus (DM) is a chronic metabolic disease that requires continuous medical attendance along with the education of patients to diminish the risk of acute and chronic complications (1). Cerebrovascular, cardiovascular, and peripheral arterial diseases are well-known chronic macrovascular complications, while nephropathy, retinopathy, and peripheral and/or autonomic neuropathy are the outcomes of microvascular damage in patients with diabetes. The lungs are also the potential targets for diabetes because the pulmonary capillary bed has a wide microvascular network and pulmonary parenchyma is rich in connective tissues. Various histopathological changes have been documented in the pulmonary structures of diabetic patients and animal models such as abnormalities of connective tissue proteins, thickening of alveolar epithelium, and changes in capillary basement membrane (2-4). Studies assessing pulmonary functions in this specific population have been increasingly reported in the recent decade (5, 6). However, results of those studies are inconsistent; while some of the studies revealed decreased pulmonary functions in diabetic patients compared with healthy controls (7-9), some studies reported similar results between diabetic and healthy individuals (10). These discrepancies could probably be attributed to the differences in study populations, such as age and duration of diabetes of the study groups, and confounders, such as status of smoking and presence of cardiovascular diseases, all of which may lead to abnormal measurements of pulmonary functions, while the actual results were in normal limits. Because the number of patients with type II DM tends to increase in developing countries, to point out the changes in pulmonary functions is crucial for subsequent preventive and therapeutical approaches.

The aim of this study was to evaluate the associations of pulmonary functions with glycemic control, duration of diabetes, and microangiopathic complications in type II diabetic patients with no history of either smoking or cardiopulmonary diseases.

Methods

The study protocol was performed in accordance with the principles of Helsinki Declaration, and informed consent was obtained from all of the participants. It was approved by the local medical ethics committee.

Consecutive type II diabetic patients on oral antidiabetic medications who were admitted to our internal medicine outpatient clinic were enrolled in our study for participation. Patients having symptoms of active respiratory system disorders, positive physical examination findings, and/or abnormal chest X-ray as well as chronic respiratory system diseases were excluded. Additionally, patients with established cardiovascular diseases, cerebrovascular disease, peripheral arterial disease, active malignancy or history of malignancy, hepatitis B and C virus infection, symptoms of active infection or inflammation, and with anemia ($Hb < 12.0$ mg/dL) as well as patients on steroid treatment were not included. Finally, during a 3-month period, a total of 31 type II diabetic patients who never smoked (24 females and 7 males) were recruited into the study.

Age, gender, body weight, and height measurements were recorded for all patients. Weight and height were measured with the same equipments; weight (kg) to the square of height (m) ratio was used for calculation of body mass index (BMI). General physical examinations were performed; arterial blood pressures were measured two times with an appropriate cuff after 10 minutes resting in an upright sitting position and the average value was recorded. Duration of diabetes and actual medications were screened from patients' interviews and hospital charts for each subject and noted down.

Venous blood samples were collected from antecubital vein after an overnight fasting period. Fasting blood glucose, hemoglobin, blood urea nitrogen (BUN), creatinine, glycosylated hemoglobin (HbA1c), and lipid parameters (total cholesterol, triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol) were determined by automated procedures conducted at the Biochemistry Department. HbA1c was assessed by high-performance liquid chromatography. Two hours after the breakfast, blood sampling was repeated for assessing the post-prandial blood glucose level.

Diabetic nephropathy was assessed by albumin excretion rates in 24 h urine specimens, and the values over 30 mg/day were accepted as diabetic nephropathy. All participants were assessed by the same ophthalmologist who was blind to the patients' characteristics and laboratory data. Besides the history of laser treatment, the presence of non-proliferative abnormalities (microaneurysm, exudate, or hemorrhage) or proliferative abnormalities with new vessel formations (neovascularization) in fundoscopic examinations were defined as diabetic retinopathy. The peripheral diabetic neuropathy was evaluated with physical examination and nerve conduction studies by the same neurologist blind to the data. Electromyographic nerve conduction studies were performed in the

tibial, peroneal, and sural nerves of the non-dominant side lower limbs of the patients. The patients with abnormalities, including both of the motor and sensory nerves, were accepted as having diabetic neuropathy.

The assessment of pulmonary functions was conducted with spirometry and diffusion capacity testing with carbon monoxide (CO). The spirometry was performed in accordance with the American Thoracic Society recommendations (11). Measurements were repeated three times, while the patients were seated upright; the highest ones for forced vital capacity [FVC] (% of predicted value) and the maximum air volume during forced expiration in 1 s [FEV_1] (% of predicted value) were taken into account. Then, the ratio of FEV_1/FVC was computed. The diffusion capacity for CO (DLco; cc/min/mmHg) from inspired air to pulmonary capillary circulation was measured using the single breath method between 08:30 and 10:00 a.m. in sitting position. Corrected DLco by alveolar ventilation was represented by $DL_{co}/\text{volume of alveoli (VA)}$ (DL_{VA}) ratio.

Statistical analysis

Statistical analysis of the presented data was performed using SPSS software (version 18 SPSS; Chicago, IL). All P values were calculated as two-sided, and values of < 0.05 were considered as statistically significant. Normality of distribution for continuous variables was tested using Kolmogorov–Smirnov test and histograms. Normally distributed parametric data were presented as mean \pm standard deviations (SD) and compared with student t-test between two groups. Non-normally distributed parametric data were presented as median and interquartile range (IQR; the range of values lying between the 25th and 75th centiles) and compared using Mann–Whitney U test. Categorical variables were shown as frequency and percentages and compared using chi-square test. Spearman or Pearson's rank correlation tests were performed to determine correlations between continuous variables. When the linear association was significant, the partial correlation analysis with the corrections of age, gender, duration of diabetes, and BMI was performed.

Results

The general characteristics of the study population are presented in Table 1. The mean age was 57.9 ± 8.5 years, median duration of diabetes was 6 (5–10) years, mean BMI was 29.69 ± 3.58 kg/m², and mean HbA1c was $9.2\% \pm 2.05\%$ in our study. As comorbid conditions, 17 patients (54%) had hypertension and 5 patients (16.1%) had hyperlipidemia. The results of blood tests and pulmonary assessments are summarized in Table 2.

Among our patients, 10 patients (32.3%) had any of the microangiopathic complications. Diabetic nephropathy was detected in 11 patients (35.4%) (nine of them had microalbuminuria and two of them had overt proteinuria); diabetic retinopathy was detected in 11 (35.4%) patients and diabetic sensorimotor neuropathy was detected in 10 of the 31 patients (32.3%). Pulmonary function tests were found to be similar between patients having microangiopathic complications and those without them. The results are presented in Table 3. HbA1c was higher in patients having complications compared with the ones having no complications (9.74 ± 2.01 vs. 8.17 ± 1.79 , respectively; $p = 0.044$).

Table 1. General characteristics, laboratory results, and pulmonary functions of the study patients

Age (years)	57.9±8.5
Gender (male; n, %)	24 (77.4%)
BMI (kg/m ²)	29.67±3.58
Systolic blood pressure (mmHg)	127.58±13.28
Diastolic blood pressure (mmHg)	78.39±9.52
Diabetes duration (year)	6 (5–10)
Comorbidities (n, %)	
Hypertension	17 (54.8%)
Hyperlipidemia	5 (16.1%)
Medications (n, %)	
Sulfonylurea	27 (87.1%)
Biguanide	17 (54.8%)
Acarbose	6 (19.4%)
Thiazolidinediones	9 (29.0%)
Renin angiotensin system blockers	8 (25.8%)
Calcium channel blockers	4 (12.9%)
Beta blockers	3 (9.7%)
Statins	4 (12.9%)
Fasting blood glucose (mg/dL)	196.45±54.51
Post-prandial blood glucose (mg/dL)	232.58±57.51
HbA1c (%)	9.24±2.05
Hemoglobin (gr/dL)	13.72±1.22
Blood urea nitrogen (mg/dL)	13.69±4.45
Creatinine (mg/dL)	0.69±0.18
Total cholesterol (mg/dL)	201.61±42.99
Triglyceride (mg/dL)	150 (104–228)
HDL-cholesterol (mg/dL)	43 (37–50)
LDL-cholesterol (mg/dL)	117.70±40.42
FEV ₁ (%)	93.88±16.12
FVC (%)	86.48±15.76
FEV ₁ /FVC	94.79±12.34
DL _{CO} (mL/min/mmHg)	104.13±15.00
DL _{VA} (mL/min/mmHg/lt)	103.26±13.00
Continuous data are presented as mean±SD or median with IQR. Categorical variables are presented as frequencies and percentages. Abbreviations: BMI: Body mass index; HbA1c: Glycosylated hemoglobin; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FEV ₁ : Forced expiratory volume in 1 s; %: Percent; FVC: Forced vital capacity; DL _{CO} : Diffusing capacity of the lungs for carbon monoxide; DL _{VA} : Per alveolar diffusion capacity (DL _{CO} adjusted for volume; DL _{CO} /volume of alveoli).	

The correlation analysis revealed reverse associations between HbA1c and mean FEV₁ and FVC values ($p=0.034$, $r=-0.383$ and $p=0.007$, $r=-0.471$, respectively), while HbA1c had positive correlations with FEV₁/FVC ratio ($p=0.018$, $r=0.424$). After adjustment for age, gender, and BMI values, these associations still remained significant. There was no association between HbA1c, DL_{CO}, and DL_{VA} values (for both $p>0.05$) and the duration of diabetes ($p=0.378$, $r=0.164$). A negative correlation was present between fasting

blood glucose level and FVC ($p=0.035$, $r=-0.380$). There was no association of fasting blood glucose level with FEV₁, FEV₁/FVC, DL_{CO}, and DL_{VA} values ($p=0.068$, $r=-0.332$; $p=0.582$, $r=0.103$; $p=0.329$, $r=0.181$; $p=0.633$, $r=0.089$, respectively).

Discussion

In the present study, the associations of glycemic control, duration of diabetes, and extrapulmonary microangiopathic complications with pulmonary functions were assessed in a cohort of non-smoking type II diabetic patients without cardiopulmonary diseases. The main finding of our study was that poor glycemic control was associated with restrictive type of functional alterations determined by spirometry. Pulmonary functions were not associated with duration of diabetes, and they were found to be similar in patients with or without microangiopathic complications.

There have been inconsistent reports concerning the relationship between glycemic control and pulmonary functions of type II diabetic patients (8-13). We have exhibited negative correlations between HbA1c, FEV₁, and FVC and positive correlations between HbA1c and FEV₁/FVC ratio. Although the mean values were in normal limits, correlations of HbA1c with spirometric parameters suggested that patients with poor glycemic control may be prone to restrictive pulmonary alterations. We did not exhibit any association between HbA1c, DL_{CO}, and DL_{VA} values in our study, as in previously reported series (12, 13). Earlier reports exerted non-significant results between HbA1c and measures of lung function (8, 10). However, in the last decade, HbA1c was manifested as a strong and consistent negative predictor of lung functions after adjusting for confounding variables in a follow-up investigation of type II diabetics (14). These discrepant results could be because of some heterogeneities of the study populations. In our study, all participants were non-smoking subjects. Moreover, correlations between HbA1c and spirometric test results remained significant after adjustment by age, gender, and BMI values, all of which may be confounding factors. Barrett et al. (10) revealed some striking results in their study. They showed that fasting plasma glucose levels were correlated with FEV₁ and FVC values in men without diabetes. Notably, we showed negative correlations of fasting blood glucose level with FVC values in our diabetic cohort. Thus, we considered that glycemic control and the level of glycemia seem to be crucial for pulmonary functions in type II diabetics.

Because of their extended capillary network, lungs could be a target for structural alterations and microvascular damage as a result of advanced glycosylation in type II diabetic patients. One of our expectations in the present study was that patients having microvascular complications of diabetes would also have worse pulmonary functions. However, we found that pulmonary functions did not differ in type II diabetic patients with or without microvascular complications. Similarly, Sinha et al. (4) detected no differences in FEV₁, FVC, and peak expiratory flow values of type II diabetic patients with one or more microangiopathic complications compared with those without any complication. In another study, FEV₁, FVC, and forced expiratory flow values have been reported to be similar in type II diabetics with or without diabetic retinopathy (12). In our study, CO transfer capacity was found to be the same in the setting of microvascular complications of diabetics. Regarding CO transfer capacity, previous reports revealed inconsistent results (15-19). Some studies exerted a decrease in CO diffusion capacity in patients with microvascular

Table 2. Laboratory results of patients according to microvascular complications

	Any Microangiopathy		Nephropathy		Retinopathy		Neuropathy	
	Yes n:21	No n:10	Yes n:11	No n:20	Yes n:11	No n:20	Yes n:10	No n:21
Age (year)	58.3±9.5	57.0±6.4	55.9±10.6	59.0±7.3	60.9±9.8	56.2±7.5	60.6±9.1	56.6±8.1
Diabetes duration (year)	7 (5.5–11.5)	5 (3.75–11.25)	7 (5–13)	6 (5–10)	7 (6–15)	5.5 (5–10)	10 (5.8–16.3)	6 (4.5–9.5)
BMI (kg/m ²)	29.05±2.99	31.02±4.48	29.06±3.06	30.03±3.87	29.56±2.96	29.76±3.95	29.49±3.34	29.78±3.77
Fasting glucose (mg/dL)	200.43±55.94	188.10±53.27	205.73±41.12	191.35±61.03	210.18±57.73	188.90±52.62	189.20±64.41	199.90±50.51
PPG (mg/dL)	227.19±59.56	243.90± 54.15	226.27±60.54	236.05±57.07	227.36±63.71	235.45±55.33	228.80±61.62	234.38±56.94
BUN (mg/dL)	13.82± 4.96	13.41±3.37	12.19±4.09	14.51±4.53	15.46±5.35	12.70±3.66	16.26±5.40	12.46±3.43*
Creatinine (mg/dL)	0.70±0.20	0.66±0.13	0.72±0.18	0.67±0.18	0.71±0.22	0.68±0.51	0.74±0.24	0.66±0.14
Hb (gr/dL)	13.51±1.13	14.15±1.36	13.85±1.38	13.65±1.16	12.99±0.78	14.12±1.25*	13.40±0.91	13.87±1.34
HbA1c (%)	9.74±2.01	8.17±1.79*	10.06±2.28	8.78±1.81	10.06±1.76	8.78±2.10	9.70±1.91	9.02 ±2.12
T. Cholesterol (mg/dL)	201.19±35.51	202.50±57.93	204.45±42.56	200.05±44.24	202.09±36.84	201.35±46.94	201.6±31.56	201.62±48.21
Triglyceride (mg/dL)	160 (98–243)	145.5 (121–175.8)	160 (87–253)	145.5 (119–192.75)	125 (94–233)	151.5 (119–219.25)	190.50 (103.5–357.25)	141 (100–188.50)
HDL-Cholesterol (mg/dL)	43 (35–49.50)	45 (39.3–50.3)	40 (35–49)	44 (40–50)	43.4 (35–50)	43 (37.75–49.75)	43.20 (34.25– 7.75)	43 (38.5–50.5)
LDL-Cholesterol (mg/dL)	115.29±36.60	122.78±49.26	118.93±41.17	117.03±41.06	120.13±27.87	116.37±46.53	107.54±32.08	122.54±43.72
FEV ₁ (%)	92.40±16.09	97.01±16.58	89.53±13.50	96.28±17.24	91.65±13.55	95.11±17.58	98.82±16.73	91.53±15.68
FVC (%)	83.95±13.24	91.80±19.79	81.35±12.02	89.31±17.09	84.09±11.53	87.8±17.8	88.85±13.34	85.36±16.97
FEV ₁ /FVC	96.86±12.65	90.44±10.99	96.06±15.03	94.09±10.95	97.59±11.97	93.25±12.56	98.56±10.63	93.00±12.92
DL _{co} (mL/min/mmHg)	104.62±15.46	103.10±14.73	104.45±17.76	103.95±13.76	102.91±15.48	104.80±15.10	106.90±14.93	102.81±15.22
DL _{va} (mL/min/mmHg/lit)	102.86±10.48	104.10±17.84	103.09±12.17	103.35±13.74	102.45±8.17	103.70±15.2	105.30±8.64	102.29±14.73

Continuous variables are presented as mean±SD or median with IQR depending on the distribution. Abbreviations; BMI: Body mass index; PPG: post prandial glucose; BUN: Blood urea nitrogen; Hb: Hemoglobin; HbA1c: Glycosylated hemoglobin; T. Cholesterol: Total cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FVC: Forced vital capacity; FEV₁: Forced expiratory volume in 1 s; DL_{co}: Diffusing capacity of the lungs for carbon monoxide; DL_{va}: Per alveolar diffusion capacity (DL_{co} adjusted for volume; DL_{co}/volume of alveoli).

*p<0.05

Table 3. The associations of HbA1c with pulmonary function tests

	r	p	r _{adj} *	p _{adj} *
FEV ₁ (%)	-0.383	0.034	-0.426	0.024
FVC (%)	-0.471	0.007	-0.482	0.009
FEV ₁ /FVC	0.424	0.018	0.415	0.028
DL _{co} (mL/min/mmHg)	0.217	0.241	0.250	0.199
DL _{va} (mL/min/mmHg/lit)	0.147	0.428	0.216	0.270

Associations were calculated by Spearman's correlation analysis. adj*: Adjusted values for age, gender, and BMI values. Abbreviations: FEV₁: Forced expiratory volume in 1 s; FVC: Forced vital capacity; DL_{co}: Diffusing capacity of the lungs for carbon monoxide; DLVA: Per alveolar diffusion capacity (DL_{co} adjusted for volume; DL_{co}/volume of alveoli).

damage including retinopathy (15, 16) and nephropathy (16, 20), while, in accordance with our results, others did not find any difference between patients with or without microvascular complications (17, 19). In this setting, Fuso et al. performed a distinctive study (21). They measured DL_{co} values separately in sitting and supine positions in type II diabetics and compared these values with those of healthy subjects. DL_{co} values were found to be increased in supine position in healthy subjects, while it was found to be the same in diabetics. Authors claimed that this postural diffusion testing could be an early method for the evaluation of pulmonary involvement in

diabetics (21). In further studies, this point should be evaluated in larger populations.

We had assumed that we would observe deterioration in pulmonary functions as a result of the prolonged exposure of vascular structures and connective tissue proteins to high blood glucose levels in correlation with duration of diabetes. However, in our study, there was no correlation between duration of diabetes and pulmonary function parameters, neither with spirometry nor with diffusion capacity. In Fremantle's study, decreases in FEV₁, FVC, and vital capacity levels were detected when the duration of diabetes increased (8). Supportively, Barrett et al. (10) showed decreased FEV₁ and FVC values in male type II DM patients for more than 10 years, while the same result could not be manifested in females. On the other hand, Benbassat et al. did not detect a relationship between duration of disease and pulmonary functions (22). Buckingham et al. (23) claimed that the decrease in vital capacity was neither related to the duration of disease nor to the presence of microvascular complications but to the structure of collagen and distortion of elasticity. Actually, defects in insulin secretion or its actions as well as pathological changes of the disease starts far before the time of diagnosis in type II diabetics. Therefore, the uncertainty in the duration of pathogenetic alterations related to diabetes could also be a confounding factor in such analyses.

Our study had some limitations, one of which was the relatively small study population. The exclusion of the patients with former

smoking history leads to a higher female/male ratio. Additionally, a relatively longer median duration of diabetes in our study could have revealed more robust results.

Conclusion

We showed that poor glycemic control was associated with restrictive alterations in the pulmonary function tests of type II diabetics. We did not observe any difference in pulmonary functions in terms of microvascular complications. Our data could support that good glycemic control is essential for the maintenance of pulmonary health in type II diabetics.

Ethics Committee Approval: Ethics committee approval was received for this study.

Informed Consent: Written informed consent was obtained from patient who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - G.U.O., E.C.Y.; Design - G.U.O., E.C.Y., A.H.; Supervision - I.S.Y.; Funding - I.S.Y.; Materials - G.U.O., I.S.Y.; Data Collection and/or Processing - G.U.O., E.C.Y., A.H., Ç.P.T.U., Y.Ç.; Analysis and/or Interpretation - G.U.O., E.C.Y., I.S.Y.; Review - G.U.O., E.C.Y.; Writer - G.U.O., E.C.Y.; Critical Review - A.H., Ç.P.T.U., Y.Ç., I.S.Y.

Acknowledgements: We would like to thank all the members of staff at our department for their valuable efforts during the study period.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Etik Kurul Onayı: Bu çalışma için etik komite onayı alınmıştır.

Hasta Onamı: Yazılı hasta onamı bu çalışmaya katılan hastalardan alınmıştır.

Hakem değerlendirmesi: Dış bağımsız.

Teşekkür: Yazarlar bölümlerinde çalışan tüm üyelere değerli katkılarından dolayı teşekkür ederler.

Yazar Katkıları: Fikir - G.U.O., E.C.Y.; Tasarım - G.U.O., E.C.Y., A.H.; Denetleme - I.S.Y.; Kaynaklar - I.S.Y.; Malzemeler - G.U.O., I.S.Y.; Veri toplanması ve/veya işlemesi - G.U.O., E.C.Y., A.H., Ç.P.T.U., Y.Ç.; Analiz ve/veya yorum - G.U.O., E.C.Y., I.S.Y.; Literatür taraması - G.U.O., E.C.Y.; Yazıyı yazan - G.U.O., E.C.Y.; Eleştirel inceleme - A.H., Ç.P.T.U., Y.Ç., I.S.Y.

Çıkar Çatışması: Yazarlar çıkar çatışması bildirmemişlerdir.

Finansal Destek: Yazarlar bu çalışma için finansal destek almadıklarını beyan etmişlerdir.

References

- Olokoba A.B, Obateru O.A, Olokoba L.B. Type 2 diabetes mellitus: a review of current trends. *Oman Med J* 2012; 27: 269-73. [CrossRef]
- Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelium and capillaries quantitative changes with aging and in diabetes mellitus. *Am Rev Respir Dis* 1979; 120: 973-83.
- Kida K, Utsuyama M, Takizawa T, Thurlbeck WM. Changes in lung morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats. *Am Rev Respir Dis* 1983; 128: 125-31.
- Sinha S, Guleria R, Misra A, Pandey RM, Yadav R, Tiwari S. Pulmonary functions in patients with type 2 diabetes mellitus and correlation with anthropometry and microvascular complications. *Indian J Med Res* 2004; 119: 66-71.
- Klein OL, Krishnan JA, Glick S, Smith LJ. Systematic review of the association between lung function and Type 2 diabetes mellitus. *Diabet Med* 2010; 27: 977-87. [CrossRef]
- Van den Borst B, Gosker H.R, Zeegers M.P, Schols A.M.W.J. Pulmonary functions in diabetes: a metaanalysis. *Chest* 2010; 138: 393-406. [CrossRef]
- Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, et al. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. *Eur Respir J* 1989; 2: 14-9.
- Davis T.M.E, Knuiman M, Kendall P, Vu H, Davis W.A. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. *Diab Res Clin Pract* 2000; 50: 153-9. [CrossRef]
- Walter RE, Beiser A, Givelber RJ, O'Connor GT, Gottlieb DJ. (2003) Association between glycemic state and lung function: the Framingham Heart Study. *Am J Respir Crit Care Med* 2003; 167: 911-6. [CrossRef]
- Barrett-Connor E, Frette C. NIDDM, impaired glucose tolerance and pulmonary function in older adults. The Rancho Bernardo Study. *Diabetes Care* 1979; 19: 1441-4. [CrossRef]
- American Thoracic Society Statement-Snowbird workshop on standardization of spirometry. *Am Rev Respir Dis* 1979; 119: 831-8.
- Ozmen B, Celik P, Yorgancıoğlu A, Ozmen B, Ozmen D, Çok G. Pulmonary function parameters in patients with diabetes mellitus. *Diabetes Res Clin Pract* 2002; 57: 209-11. [CrossRef]
- Mori H, Okubo M, Okamura M, Yamane K, Kado S, Egusa G, et al. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. *Intern Med* 1992; 31: 189-93. [CrossRef]
- Davis W.A, Knuiman M, Kendall P, Grange V, Davis T.M. Fremantle Diabetes Study Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Care* 2004; 27: 752-7. [CrossRef]
- Asanuma Y, Fujiya S, Ide H, Agishi Y. Characteristics of pulmonary function in patients with diabetes mellitus. *Diabetes Res Clin Pract* 1985; 1: 95-101. [CrossRef]
- Marvisi M, Bartolini L, del Borrello P, Brianti M, Marani G, Guariglia A, et al. Pulmonary function in non-insulin-dependent diabetes mellitus. *Respiration* 2001; 68: 268-72. [CrossRef]
- Minette P, Buyschaert M, Rahier J, Veriter C, Frans A. Pulmonary gas exchange in life-long nonsmoking patients with diabetes mellitus. *Respiration* 1999; 66: 20-4. [CrossRef]
- Maccioni FJ, Colebatch HJ. Lung volume and distensibility in insulin dependent diabetes mellitus. *Am Rev Respir Dis* 1991; 143: 1253-6. [CrossRef]
- Arı G, İtil O, Çömlekçi A, Özdoğan Ö, Değirmenci B, Yeşil S, et al. Tip 2 Diabetes Mellituslu Hastalarda Solunum Fonksiyon Testi ve İnhalasyon Perfüzyon Sintiğrafisi Bulguları. *Toraks Dergisi* 2002; 3: 257-65.
- Ljubic S, Metelko Z, Car N, Roglic G, Drazic Z. Reduction of diffusion capacity for carbon monoxide in diabetic patients. *Chest* 1998; 114: 1033-5. [CrossRef]
- Fuso L, Cotroneo P, Basso S, De Rosa M, Manto A, Ghirlanda G. Postural variations of pulmonary diffusing capacity in insulin-dependent diabetes mellitus. *Chest* 1996; 110: 1009-13. [CrossRef]
- Benbassat C, Stern E, Kramer M, Lebzelter J, Blum I, Fink G. Pulmonary function in patients with diabetes mellitus. *Am J Med Sci* 2001; 322: 127-32. [CrossRef]
- Buckingham B, Perejda A.J, Sandborg C, Kershner A.K, Uitto J. Skin, joint and pulmonary changes in type I Diabetes mellitus. *Am J Dis Child* 1986; 140: 420-3. [CrossRef]